ReviewJournal of investigative medicine : the official publication of the American Federation for Clinical Research2021
Advances in the management of pulmonary arterial hypertension.
Review in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis.Health and quality of life outcomes · 2026Pooled it
- Artificial intelligence in pulmonary hypertension: a systematic review.European journal of medical research · 2025Pooled it
- Pulmonary hypertension survival and hospitalisations in people living with HIV: a systematic review and meta-analysis.BMJ open respiratory research · 2024Pooled it
- Machine learning for prediction of key haemodynamic parameters in pulmonary arterial hypertension.European heart journal. Digital health · 2026Article
- NT-proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point-of-Care and Remote Monitoring.Respirology (Carlton, Vic.) · 2025Observational
- Important Differences in Disease Severity, Echocardiography Findings, and Referral Delays in Non-Hispanic Black Patients With Pulmonary Arterial Hypertension.Pulmonary circulation · 2025Article
- Performance of Risk-Stratification Scores for Patients With Pulmonary Arterial Hypertension in a Multi-Ethnic Asian Population.Pulmonary circulation · 2025Article
- Pulmonary Shunt in Critical Care: A Comprehensive Review of Pathophysiology, Diagnosis, and Management Strategies.Cureus · 2024Review
- Article
- NDRG1 promotes endothelial dysfunction and hypoxia-induced pulmonary hypertension by targeting TAF15.Precision clinical medicine · 2023Article
- Article
- Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD).Pulmonary circulation · 2023Article
- A claims-based, machine-learning algorithm to identify patients with pulmonary arterial hypertension.Pulmonary circulation · 2023Article
- Why Living with Pulmonary Arterial Hypertension Requires a Holistic Approach: A Patient and Clinician Perspective.Pulmonary therapy · 2023Article
- The sine transform is theFrontiers in cardiovascular medicine · 2023Article
- Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil registry (RESPHIRAR study).Pulmonary circulation · 2023Article
- Treating Inflammation Associated with Pulmonary Hypertension: An Overview of the Literature.International journal of general medicine · 2022Review
- Hypoxia driven opioid targeted automated device for overdose rescue.Scientific reports · 2021Article
- Impression life with pulmonary hypertension: clinically relevant characteristics and quality of life among patients in Gansu, China.Therapeutic advances in respiratory diseaseObservational
- The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of pulmonary arterial hypertension (PAH) has significantly evolved over the last decades in the wake of more sensitive diagnostics and specialized clinical programs that can provide focused medical care. In the current era of PAH care, 1-year survival rates have increased to 86%-90% from 65% in the 1980s, and average long-term survival has increased to 6 years from 2.8 years. The heterogeneity in the etiology and disease course has opened doors to focusing research in phenotyping the disease and understanding the pathophysiology at a cellular and genetic level. This may eventually lead to precision medicine and the development of medications that may prevent or reverse pulmonary vascular remodeling. With more insight, clinical trial designs and primary end-points may change to identify the true survival benefit of pharmacotherapy. Identifying responders from non-responders to therapy may help provide individualized patient-centered care rather than an algorithm-based approach. The purpose of this review is to highlight the latest advances in screening, diagnosis, and management of PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.